|Videos|April 7, 2023
Considerations in Treatment Selection for BCC
Experts in dermatology comment on their considerations relating to treatment selection in their patients with basal cell carcinoma, highlighting the impact of cemipulab in this space.
Advertisement
Episodes in this series
Advertisement
Related to this article
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Advertisement
Advertisement
Trending on Dermatology Times
1
Clinicians Debate JAK Inhibitor Selection in Alopecia Areata
2
Menopause and the Skin: Recognizing Changes Beyond Aging
3
Social Media Mythbusters: Can Face Taping Really Prevent Wrinkles?
4
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
5